Although baseline diagnosis was controlled statistically in the statistical modelling, it will be important for future studies with larger sample sizes to clarify the role of BDNF Val66Met on changes in tau and memory across the preclinical, prodromal, and dementia stages of AD. This evidence concerns the gene MAPT and Alzheimer disease.